Caco-2 based in vitro models for the screening of anti-inflammatory drugs

31 May 2022
Lourdes Gombau | R&D Director

Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD), a term that describe disorders that involve chronic inflammation of the digestive tract. The release of a complex network of mediators (cytokines, chemokines, growth factors, adhesion molecules and neuropeptides) produced by the intestinal epithelial cells as well as by immune-related cells and other cell types of the lamina propia are the major features of this inflammatory process.

The use of cell-based assays that can provide valuable insights into the efficacy of anti-inflammatory drugs to treat intestinal inflammation requires a cell model which closely resembles the in vivo IDB. Caco-2 based models, either those only including the absorptive cell phenotype (Caco-2) or the co-cultures of enterocytes and mucus-secreting cells (Caco-2/HT29 MTX) have been shown to be useful to conduct these kinds of studies since they are both responsive to pro-inflammatory stimulation, producing a wide range of intestinal mediators and increasing the paracellular permeability.

Flavanols, flavonols and anthocyanidins obtained from natural products such as plant and wine extracts are some examples of compounds that have been reported to have anti-inflammatory properties on Caco-2 based models previously exposed to inflammatory mediators (TNFα, IL1β, LPS). They prevent or reduce the synthesis and release of the inflammatory cytokines IL-6 and IL-8 and protect from intestinal permeability alterations. Chlorogenic acid, a polyphenol found in coffee and black tea has also been described to inhibit TNFα- and H2O2-induced IL-8 production in Caco-2 cells while a Bubalus bubalis milk-derived peptide help to restore the intestinal epithelium integrity in inflamed Caco-2 cells and in a dinitrobenzene sulfonic acid (DNBS) mice model of colitis.

ReadyCell has available CacoGoblet to assay compounds inflammatory properties. This ready-to-use cell-based model is established with differentiated human colorectal carcinoma cells (Caco-2 and HT29 cells) that mimic the morphological and functional properties of the intestinal barrier in vivo. The model is preplated and differentiated on transwell insert plates and delivered worldwide by means of our patented gel-like Shipping Medium®.

For more information, contact our expert team at reagents@readycell.com

Additional readings

Related posts

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).

Caco-2 Permeability Assay Protocol

Caco-2 Permeability Assay Protocol

Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.

New hyperoxia drug study references CacoReady Kits

New hyperoxia drug study references CacoReady Kits

The publication, entitled Daily Intraperitoneal Administration of RGZ Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.